Navigation Links
Hiker without Human Heart Receives Heart Transplant 607 Miles Later
Date:11/15/2012

TUCSON, Ariz., Nov. 15, 2012 /PRNewswire/ -- SynCardia Systems, Inc. (www.syncardia.com), manufacturer of the world's first and only FDA, Health Canada and CE (Europe) approved Total Artificial Heart, announced today that avid hiker Chris Marshall, who received the SynCardia temporary Total Artificial Heart in February, has been successfully bridged to a heart transplant at University of Washington (UW) Medical Center in Seattle.

(Photo: http://photos.prnewswire.com/prnh/20121115/LA13969)  

Watch video from NBC Seattle -

http://www.syncardia.com/News/avid-hiker-with-total-artificial-heart-receives-transplant.html

"I walked 607 miles with the Total Artificial Heart, so I was really fit going into that surgery," said Mr. Marshall, who received his heart transplant on Sept. 12. "That's very different from a lot of people who go into the transplant really sick. After the surgery, they not only have to recover from the transplant, but also from being sick for so long leading up to it."

Mr. Marshall was implanted with the SynCardia Total Artificial Heart on Feb. 6. Seven weeks later, on March 21, he became the first Total Artificial Heart patient in the Pacific Northwest to be discharged from the hospital using the Freedom® portable driver to power his Total Artificial Heart. After his discharge, Mr. Marshall hiked daily in the Seattle area with his wife Kathy and their golden retriever Gracie.

When asked what advice he has for other Total Artificial Heart patients, Mr. Marshall said, "Don't go home and stay cooped up. You need to get out and take advantage of the time you have to get in shape to prepare for the transplant surgery and live life. Some people are afraid. The only thing they want to do is be home or go to the clinic for visits, but for me, that's not living life."

In 1999, Mr. Marshall was diagnosed with cardiomyopathy, a disease that destroys the heart muscle over time, and ventricular tachycardia, an irregular, fast heartbeat. Although his implanted defibrillator shocked his heart 30 times over a 12-year span, Mr. Marshall never let his heart condition slow him down. He continued to hike three to five miles daily, despite his ejection fraction being only 20%.

However, last fall, he started experiencing shortness of breath while hiking on level ground, which had never happened before. On Jan. 23, Mr. Marshall and his wife Kathy traveled from their home in Wasilla, Alaska, to Seattle for what was supposed to be a one-day heart evaluation. Doctors discovered his heart was functioning at less than 10 percent, and didn't think he would survive the flight home.

Mr. Marshall was not a candidate for a left ventricular assist device (LVAD) - a mechanical pump that supports only the left side of the heart - because the right side of his heart was too weak. His doctors decided the SynCardia Total Artificial Heart was his only option for survival.

Weighing 13.5 pounds (~6 kg), the Freedom portable driver is the world's first wearable power supply for the SynCardia Total Artificial Heart. The Freedom portable driver is CE approved for use in Europe and undergoing an FDA-approved Investigational Device Exemption (IDE) clinical study in the U.S.

Read article in The Seattle Times - http://seattletimes.com/html/localnews/2019139640_hearttransplant13m.html

View press release from UW Medical Center - http://www.washington.edu/news/2012/09/13/after-months-on-portable-artificial-heart-alaska-man-receives-transplant/

CAUTION – The Freedom portable driver is an investigational device, limited by United States law to investigational use.

Like SynCardia on Facebook
Follow SynCardia on Twitter – @SynCardia
Connect with SynCardia on LinkedIn

About the SynCardia temporary Total Artificial Heart

SynCardia Systems, Inc. (Tucson, AZ) is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart. Originally used as a permanent replacement heart, SynCardia's Total Artificial Heart is currently approved as a bridge to transplant for people dying from end-stage biventricular heart failure. There have been more than 1,000 implants of the Total Artificial Heart, accounting for more than 270 patient years of life.

Similar to a heart transplant, SynCardia's Total Artificial Heart replaces both failing heart ventricles and the four heart valves, eliminating the symptoms and source of end-stage biventricular failure. Unlike a donor heart, the Total Artificial Heart is immediately available at SynCardia Certified Centers. It is the only device that provides immediate, safe blood flow of up to 9.5 liters per minute through each ventricle. This high volume of safe blood flow helps speed the recovery of vital organs, helping make the patient a better transplant candidate.

 

 


'/>"/>
SOURCE SynCardia Systems, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Without Environmental Hygiene, Hand Hygiene Programs Fall Short in Reducing HAIs in Hospital Settings, Says UMF Corporation
2. LIVE VIA SATELLITE: Physician Demonstrates New Medical Technology to Combat Back Pain without Major Surgery
3. Man Without Human Heart Hikes More Than 400 Miles
4. Homecare Community Dismayed that Medicare Will Start Prior Authorization for Wheelchairs without a Clinical Template for Physicians to Document Need
5. RMANJ Research Demonstrates That Egg Freezing Prior To IVF Yields Positive Outcomes Without Increasing Risk Of Aneuploidy
6. Mount Sinai Medical Center 1st in Tri-State Area to Discharge Patient without Human Heart
7. Netsmarts Focus on Innovation to Help Health and Human Service Providers Span the Spectrum of Care in the Healthcare 3.0 Environment
8. SMT C1100 For Duchenne Muscular Dystrophy Moves To Human Testing
9. Global Human Vaccines Industry
10. ReproCELL Launches Alzheimers Disease Model Based on iPS-derived Human Neuronal Cells
11. HemoShear Publishes Key Review on Human-Relevant Organotypic Systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/12/2017)... Kineta, Inc., a biotechnology company focused on the ... President of R&D and Head of Virology Kristin Bedard has ... the Northwest and Beyond meeting sponsored by Life Science ... from 8:30-10:30 AM PDT at the Agora Conference Center in ... Bedard will be joined by other leaders in infectious disease ...
(Date:6/9/2017)... , June 9, 2017 More than ... further effort to help spread lessons learned from clinical ... International Diabetes Federation (IDF) and Eli Lilly and Company ... the second phase of the Bringing Research in Diabetes ... their commitment to helping people with diabetes effectively manage ...
(Date:6/7/2017)... -- Endo International plc (NASDAQ: ENDP ) ... Joseph R. Goodwin , U.S. District Court Judge for ... , entered a case management order in MDL 2325, ... Litigation (the "MDL") that includes a provision requiring plaintiffs ... on specific causation within one hundred twenty (120) days ...
Breaking Medicine Technology:
(Date:6/28/2017)... ... 28, 2017 , ... Park Systems , a leader in Atomic Force ... attendees and Park customers on July 11, 2017 from 12-2pm at the Thirsty ... & CEO of Park Systems, and Prof. Krishna Saraswat , Rickey/Nielsen Professor in ...
(Date:6/28/2017)... ... June 28, 2017 , ... Schneider Insurance and ... to clients in southern Montana, is announcing a focused charity effort to gather ... outreach programs offered by Zoo Montana provide students with current knowledge on the ...
(Date:6/28/2017)... VA (PRWEB) , ... June 28, 2017 , ... ... protection assistance and financial consultations to communities in northern Virginia and DC, is ... to help provide for patients with Alzheimer’s and other disorders that lead to ...
(Date:6/27/2017)... ... 27, 2017 , ... Excel Medical, the leader in Next-Generation ... of Executive Vice President, Sales and Marketing. Finnegan is a widely known industry ... sales leadership. He has received industry recognition for innovations and new approaches to ...
(Date:6/27/2017)... and London UK (PRWEB) , ... June 27, 2017 , ... ... to a clinical study is whether they can trust the sponsor to pay them ... is vital that sponsors and CROs establish payment strategies that encourage sites to work ...
Breaking Medicine News(10 mins):